Shibuya M, Saito F, Miwa T, Davis R L, Wilson C B, Hoshino T
Department of Neurological Surgery, School of Medicine, University of California, San Francisco 94143.
Acta Neuropathol. 1992;84(2):178-83. doi: 10.1007/BF00311392.
The growth potential of 65 pituitary adenomas was determined by histochemical analysis with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine (BrdUdR) labeling, and counts of argyrophilic nucleolar organizer regions (Ag-NORs). The mean proliferating cell indices (PCIs) determined by Ki-67 and anti-DNA polymerase alpha and the BrdUdR labeling index (LI) were generally very low [1.0 +/- 0.2%, 1.1 +/- 0.2%, and 0.5 +/- 0.1% (+/- SE), respectively]. Apart from adrenocorticotropic hormone-positive adenomas, which had significantly higher indices, there were no statistically significant differences in the indices among the other subtypes of pituitary adenomas. Recurrent tumors had higher Ki-67 and DNA polymerase alpha PCIs and BrdUdR LIs (3.6%, 4.2%, 1.4%) than primary tumors (0.8%, 0.8%, 0.3%; P less than 0.005). The number of Ag-NORs did not correlate significantly with any of the three indices. The mean number of Ag-NORs was higher in nonfunctioning adenomas than in functioning adenomas (2.04 vs 1.66, P less than 0.005); among prolactin-positive adenomas, those treated preoperatively with bromocriptine had more Ag-NORs than untreated tumors (1.75 vs 1.57, P less than 0.005). These results suggest that the Ki-67 and DNA polymerase alpha PCIs and the BrdUdR LI predict the growth potential of individual pituitary adenomas, whereas the number of Ag-NORs appears to correlate with hormone production rather than with the proliferative potential.
采用Ki-67和抗DNA聚合酶α单克隆抗体进行组织化学分析、溴脱氧尿苷(BrdUdR)标记以及嗜银核仁组织区(Ag-NORs)计数,来确定65例垂体腺瘤的生长潜能。通过Ki-67和抗DNA聚合酶α测定的平均增殖细胞指数(PCI)以及BrdUdR标记指数(LI)通常非常低[分别为1.0±0.2%、1.1±0.2%和0.5±0.1%(±标准误)]。除促肾上腺皮质激素阳性腺瘤的指数显著较高外,其他亚型的垂体腺瘤之间的指数无统计学显著差异。复发性肿瘤的Ki-67和DNA聚合酶α PCI以及BrdUdR LI(3.6%、4.2%、1.4%)高于原发性肿瘤(0.8%、0.8%、0.3%;P<0.005)。Ag-NORs的数量与这三个指数中的任何一个均无显著相关性。无功能腺瘤的Ag-NORs平均数量高于有功能腺瘤(2.04对1.66,P<0.005);在催乳素阳性腺瘤中,术前接受溴隐亭治疗的肿瘤比未治疗的肿瘤有更多的Ag-NORs(1.75对1.57,P<0.005)。这些结果表明,Ki-67和DNA聚合酶α PCI以及BrdUdR LI可预测个体垂体腺瘤的生长潜能,而Ag-NORs的数量似乎与激素产生相关,而非与增殖潜能相关。